Article info

Cost-effectiveness of ranibizumab and bevacizumab for age-related macular degeneration: 2-year findings from the IVAN randomised trial

Authors

  1. Correspondence to Helen A Dakin; helen.dakin{at}dph.ox.ac.uk
View Full Text

Citation

Dakin HA, Wordsworth S, Rogers CA, et al
Cost-effectiveness of ranibizumab and bevacizumab for age-related macular degeneration: 2-year findings from the IVAN randomised trial

Publication history

  • Received February 19, 2014
  • Revised June 19, 2014
  • Accepted June 23, 2014
  • First published July 29, 2014.
Online issue publication 
July 29, 2014
  • Supplementary Data

    This web only file has been produced by the BMJ Publishing Group from an electronic file supplied by the author(s) and has not been edited for content.

    Files in this Data Supplement:

Request permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.